- Home
- HBIO vs CVKD Comparison
HBIO vs CVKD Comparison
Compare HBIO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- CVKD
- Stock Information
- Founded
- HBIO 1901
- CVKD 2022
- Country
- HBIO United States
- CVKD United States
- Employees
- HBIO N/A
- CVKD N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- HBIO Industrials
- CVKD Health Care
- Exchange
- HBIO Nasdaq
- CVKD Nasdaq
- Market Cap
- HBIO 24.6M
- CVKD 23.4M
- IPO Year
- HBIO 2000
- CVKD 2023
- Fundamental
- Price
- HBIO $0.76
- CVKD $9.63
- Analyst Decision
- HBIO Buy
- CVKD Strong Buy
- Analyst Count
- HBIO 3
- CVKD 1
- Target Price
- HBIO $2.50
- CVKD $32.00
- AVG Volume (30 Days)
- HBIO 18.9M
- CVKD 18.4K
- Earning Date
- HBIO 11-06-2025
- CVKD 11-10-2025
- Dividend Yield
- HBIO N/A
- CVKD N/A
- EPS Growth
- HBIO N/A
- CVKD N/A
- EPS
- HBIO N/A
- CVKD N/A
- Revenue
- HBIO $87,371,000.00
- CVKD N/A
- Revenue This Year
- HBIO N/A
- CVKD N/A
- Revenue Next Year
- HBIO $7.02
- CVKD N/A
- P/E Ratio
- HBIO N/A
- CVKD N/A
- Revenue Growth
- HBIO N/A
- CVKD N/A
- 52 Week Low
- HBIO $0.28
- CVKD $8.74
- 52 Week High
- HBIO $2.38
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- HBIO 66.85
- CVKD 27.07
- Support Level
- HBIO $0.56
- CVKD $10.01
- Resistance Level
- HBIO $0.74
- CVKD $11.29
- Average True Range (ATR)
- HBIO 0.08
- CVKD 0.85
- MACD
- HBIO 0.01
- CVKD -0.24
- Stochastic Oscillator
- HBIO 95.47
- CVKD 0.28
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.